Alaunos Therapeutics says it regains compliance with Nasdaq stockholders' equity requirement
TCRT•Alaunos Therapeutics believes it has regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement after a $350 million financing closed on October 14, 2026. Nasdaq confirmation is pending, and continued listing remains at risk if the fiscal 2026 annual report fails to show compliance.
1. Compliance remains pending
Alaunos Therapeutics said it believes it has regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement. The company cited a $350 million financing that closed October 14, 2026, and a cash settlement waiver covering approximately $9 million of preferred stock. Nasdaq confirmation remains pending; the November 10, 2026, delisting hearing is expected to be canceled upon confirmation, but continued listing remains at risk if the fiscal 2026 annual report fails to demonstrate compliance.
